About Adaptate Biotherapeutics
Adaptate Biotherapeutics is a company based in London (United Kingdom) founded in 2019 was acquired by Takeda in January 2022.. Adaptate Biotherapeutics has raised $18 million across 1 funding round from investors including Takeda Pharmaceuticals, Abingworth and Takeda Pharmaceutical. The company has 21 employees as of March 31, 2022. Adaptate Biotherapeutics offers products and services including Rusfertide. Adaptate Biotherapeutics operates in a competitive market with competitors including Poseida Therapeutics, Celgene, TScan Therapeutics, Sonoma Biotherapeutics and ArsenalBio, among others.
- Headquarter London, United Kingdom
- Employees 21 as on 31 Mar, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adaptate Biotherapeutics Ltd
- Date of Incorporation 21 Aug, 2019
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$18 M (USD)
in 1 rounds
-
Latest Funding Round
$18 M (USD), Series A
Apr 19, 2021
-
Investors
Takeda Pharmaceuticals
& 2 more
-
Employee Count
21
as on Mar 31, 2022
-
Acquired by
Takeda
(Jan 10, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Adaptate Biotherapeutics
Adaptate Biotherapeutics offers a comprehensive portfolio of products and services, including Rusfertide. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for polycythemia vera and related blood disorders
Funding Insights of Adaptate Biotherapeutics
Adaptate Biotherapeutics has successfully raised a total of $18M through 1 strategic funding round. The most recent funding activity was a Series A round of $18 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $18.0M
-
First Round
First Round
(19 Apr 2021)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Series A - Adaptate Biotherapeutics | Valuation | Abingworth , Takeda Pharmaceutical |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adaptate Biotherapeutics
Adaptate Biotherapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, Abingworth and Takeda Pharmaceutical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adaptate Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Adaptate Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adaptate Biotherapeutics Comparisons
Competitors of Adaptate Biotherapeutics
Adaptate Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Celgene, TScan Therapeutics, Sonoma Biotherapeutics and ArsenalBio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Therapies for cancer and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immune cell therapies
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adaptate Biotherapeutics
Frequently Asked Questions about Adaptate Biotherapeutics
When was Adaptate Biotherapeutics founded?
Adaptate Biotherapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Adaptate Biotherapeutics located?
Adaptate Biotherapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Is Adaptate Biotherapeutics a funded company?
Adaptate Biotherapeutics is a funded company, having raised a total of $18M across 1 funding round to date. The company's 1st funding round was a Series A of $18M, raised on Apr 19, 2021.
How many employees does Adaptate Biotherapeutics have?
As of Mar 31, 2022, the latest employee count at Adaptate Biotherapeutics is 21.
What does Adaptate Biotherapeutics do?
Founded in 2019 and based in London, United Kingdom, T-cell-based immunotherapies for cancer are developed. Antibodies are created to target gamma delta T cells, a type of lymphocyte. These cells are engaged to recognize malignant cells through patterns of markers on dysregulated, transformed tissues. Operations center on advancing this biotechnology sector approach for oncology applications.
Who are the top competitors of Adaptate Biotherapeutics?
Adaptate Biotherapeutics's top competitors include Achilles Therapeutics, GigaGen and Shattuck Labs.
What products or services does Adaptate Biotherapeutics offer?
Adaptate Biotherapeutics offers Rusfertide.
Who are Adaptate Biotherapeutics's investors?
Adaptate Biotherapeutics has 3 investors. Key investors include Takeda Pharmaceuticals, Abingworth, and Takeda Pharmaceutical.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.